01702nas a2200313 4500008004100000022001400041245005100055210004900106260001200155300001200167490000700179520077800186653001200964653002600976653002601002653001101028653001801039653001401057653002601071653002101097653002401118100002301142700002201165700001901187700002001206700002401226700001701250856012101267 2021 eng d a1474-178400aTargeting Notch in oncology: the path forward.0 aTargeting Notch in oncology the path forward c2021 02 a125-1440 v203 a
Notch signalling is involved in many aspects of cancer biology, including angiogenesis, tumour immunity and the maintenance of cancer stem-like cells. In addition, Notch can function as an oncogene and a tumour suppressor in different cancers and in different cell populations within the same tumour. Despite promising preclinical results and early-phase clinical trials, the goal of developing safe, effective, tumour-selective Notch-targeting agents for clinical use remains elusive. However, our continually improving understanding of Notch signalling in specific cancers, individual cancer cases and different cell populations, as well as crosstalk between pathways, is aiding the discovery and development of novel investigational Notch-targeted therapeutics.
10aAnimals10aAntineoplastic Agents10aDrug Delivery Systems10aHumans10aImmunotherapy10aNeoplasms10aNeoplastic Stem Cells10aReceptors, Notch10aSignal Transduction1 aMajumder, Samarpan1 aCrabtree, Judy, S1 aGolde, Todd, E1 aMinter, Lisa, M1 aOsborne, Barbara, A1 aMiele, Lucio uhttps://www.umass.edu/veterinary-animal-sciences/research-faculty/publications/targeting-notch-oncology-path-forward